AGL 39.58 Decreased By ▼ -0.42 (-1.05%)
AIRLINK 131.22 Increased By ▲ 2.16 (1.67%)
BOP 6.81 Increased By ▲ 0.06 (0.89%)
CNERGY 4.71 Increased By ▲ 0.22 (4.9%)
DCL 8.44 Decreased By ▼ -0.11 (-1.29%)
DFML 41.47 Increased By ▲ 0.65 (1.59%)
DGKC 82.09 Increased By ▲ 1.13 (1.4%)
FCCL 33.10 Increased By ▲ 0.33 (1.01%)
FFBL 72.87 Decreased By ▼ -1.56 (-2.1%)
FFL 12.26 Increased By ▲ 0.52 (4.43%)
HUBC 110.74 Increased By ▲ 1.16 (1.06%)
HUMNL 14.51 Increased By ▲ 0.76 (5.53%)
KEL 5.19 Decreased By ▼ -0.12 (-2.26%)
KOSM 7.61 Decreased By ▼ -0.11 (-1.42%)
MLCF 38.90 Increased By ▲ 0.30 (0.78%)
NBP 64.01 Increased By ▲ 0.50 (0.79%)
OGDC 192.82 Decreased By ▼ -1.87 (-0.96%)
PAEL 25.68 Decreased By ▼ -0.03 (-0.12%)
PIBTL 7.34 Decreased By ▼ -0.05 (-0.68%)
PPL 154.07 Decreased By ▼ -1.38 (-0.89%)
PRL 25.83 Increased By ▲ 0.04 (0.16%)
PTC 17.81 Increased By ▲ 0.31 (1.77%)
SEARL 82.30 Increased By ▲ 3.65 (4.64%)
TELE 7.76 Decreased By ▼ -0.10 (-1.27%)
TOMCL 33.46 Decreased By ▼ -0.27 (-0.8%)
TPLP 8.49 Increased By ▲ 0.09 (1.07%)
TREET 16.62 Increased By ▲ 0.35 (2.15%)
TRG 57.40 Decreased By ▼ -0.82 (-1.41%)
UNITY 27.51 Increased By ▲ 0.02 (0.07%)
WTL 1.37 Decreased By ▼ -0.02 (-1.44%)
BR100 10,504 Increased By 59.3 (0.57%)
BR30 31,226 Increased By 36.9 (0.12%)
KSE100 98,080 Increased By 281.6 (0.29%)
KSE30 30,559 Increased By 78 (0.26%)

Spanish biotechnology firm Zeltia is in talks with three companies to sell the licence for its Kahalalide F drug to treat acute psoriasis, its chairman said on Monday. "We've decided that Kahalalide be used to treat psoriasis, where we've seen a very positive reaction," Jose Maria Fernandez Sousa told Reuters in an interview.
Kahalalide F is currently in Phase II trials for the treatment of acute psoriasis. It had originally been developed for use against lung cancer and melanoma, but Zeltia has decided not to pursue those applications.
Zeltia has decided to shift Kahalalide F for dermatological use as its cancer research unit PharmaMar focuses on its speciality: anti-cancer compounds derived from marine organisms. Yondelis, PharmaMar's star drug, is already sold to treat soft tissue sarcoma, a rare and usually fatal form of cancer that attacks muscles, fat or blood vessels.
Zeltia plans to submit Yondelis for the treatment of ovarian cancer to the EMEA (European Medicines Agency) between mid-November and mid-December, Fernandez Sousa said, with approval expected in 2009. "We should have approval by next year and start selling for ovarian cancer in the second half or by the end of next year," he said.
Partner Johnson & Johnson will file for FDA approval around the same time. If Yondelis is approved for ovarian cancer treatment, the drug will have a sales potential of 1 billion euros a year, a target which Fernandez-Sousa hopes to reach by 2012. "We don't have a crystal ball ... but the potential is there," he said.

Copyright Reuters, 2008

Comments

Comments are closed.